الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 89 |  |  |
| | | from | 89 | | |
Abstract
A huge consequence of liver cirrhosis is HCC. People with HCV cirrhosis have a 3-5 percent annual incidence of HCC. For this reason, from a diagnostic and prognostic standpoint, it is extremely valuable to evaluate biomarkers that predict the early onset of HCC in cirrhotic patients.
Despite having a low sensitivity and positive predictive value, AFP used as a indicator for HCC. Furthermore, normal α-fetoprotein levels are thought to be present in up to 30% of HCC patients. Consequently, the introduction of novel biomarkers is required for the quick diagnosis of HCC cases.
Serum M2BPGI is a useful serum marker for HCC can be used as marker of diagnosis and prognosis as well. M2BP is an extracellular matrix cell adhesive glycoprotein produced as a galectin 3 ligand. Several types of cells particularly liver cells, produce it(110) .It is believed to represent fibrosis in chronic hepatic disease and the likelihood of developing HCC in people with chronic HCV.
This research was done to study the changes in serum M2BPGI in HCV induced liver cirrhosis and HCC and to evaluate its role as an emerging novel biomarker of HCC in comparison to AFP.
The study was carried out on 90 subjects in Alexandria Main University Hospital, Tropical Medicine Department; the subjects were separated into two groups. The two groups consisted of 45 patients each. group I: 45 patients with liver cirrhosis induced by HCV without HCC. group II:45 patients who had HCC and hepatic cirrhosis caused by HCV.
Patients with hepatic cirrhosis due to other cause than HCV or having PBC and PSC were excluded from the study.